Cargando…
Cardiac Steatosis in HIV-A Marker or Mediator of Disease?
Although people living with HIV (PLHIV) are approaching normal life expectancy, a limitation to achieving this goal is managing the higher prevalence of co-morbidities, including cardiovascular disease. Whilst ischaemic heart disease likely contributes to a large proportion of cardiac disease in the...
Autores principales: | Jacob, Morgan, Holloway, Cameron J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193415/ https://www.ncbi.nlm.nih.gov/pubmed/30364255 http://dx.doi.org/10.3389/fendo.2018.00529 |
Ejemplares similares
-
Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease
por: Marti-Aguado, David, et al.
Publicado: (2023) -
Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease
por: Jiang, Meng, et al.
Publicado: (2019) -
Relationship Between Non-Alcoholic Fatty Liver Disease and Degree of Hepatic Steatosis and Bone Mineral Density
por: Xie, Ruijie, et al.
Publicado: (2022) -
Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease
por: Semmler, Georg, et al.
Publicado: (2023) -
Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
por: Pan, Chelsea S., et al.
Publicado: (2020)